Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of FFP104 in moderate to severe active Crohn's disease
NL-OMON43739Phase 2Recruiting
- Sponsor
- Fast Forward Pharmaceuticals BV
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FFP104 in Crohn's disease and inflammatory bowel disease (IBD) (3 arms), sponsored by Fast Forward Pharmaceuticals BV. Primary endpoint: Safety and efficacy of FFP104. Started Nov 2016; status: recruiting.
02
Drugs
FFP104
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON43739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43739.